资源描述：
《Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、Clinicalreport1Abirateroneinheavilypretreatedpatientswithmetastaticcastrate-resistantprostatecancerabcdEdoardoFrancini,AnnaIdaFiaschi,RobertoPetrioli,FilippoFrancini,acccVincenzoBianco,ArmandoPerrella,GiovanniPaganini,LetiziaLaeracandGiandomenicoRovielloTheaimofthisstu
2、dywastoevaluatetheactivitythenumberofchemotherapylinesadministeredandtolerabilityofabirateroneacetateinpatientswithpreviously.Anti-CancerDrugs00:000–000c2014Woltersmetastaticcastrate-resistantprostatecancertreatedKluwerHealth
3、LippincottWilliams&Wilkins.previouslywithmo
4、rethanthreelinesofchemotherapy.Anti-CancerDrugs2014,00:000–000Patientsreceived1gofabirateroneacetate(administeredasfour250mgtablets)orallyoncedailywithprednisoneatKeywords:abirateroneacetate,castrate-resistantprostatecancer,prostate-specificantigenadoseof5mgorallytwice
5、daily.Theprimaryendpointwasaprostate-specificantigen(PSA)response.FromAugustMedicalOncologyUnit,PoliclinicoUmbertoIHospital,UniversityofRome,bcRome,PharmacologyUnit,MedicalOncologyUnit,UniversityofSienaand2011toJanuary2013,36patientswereenrolled.PSAdDepartmentofOdontos
6、tomatologyandMaxillo-FacialSurgery,Universityresponsewasobservedin22patients(61.1%,95%ofSiena,Siena,Italyconfidenceinterval:0.41–0.81).ThemediantimetoPSACorrespondencetoEdoardoFrancini,MD,MedicalOncologyUnit,Policlinicoprogressionwas7.3monthsandafteramedianfollow-upUmb
7、ertoIHospital,UniversityofRome,ViadelPoliclinico155,00161Rome,Italyof10.1months,allpatientswerealive.ThetreatmentwasTel:+393497735841;fax:+390577586429;generallywelltolerated;sideeffectssecondarytoe-mail:edoardofrancini@gmail.comandmineralocorticoidexcessresultingfromb
8、lockadeofCYP17GiandomenicoRoviello,MD,MedicalOncologyUnit,UniversityofSiena,werelargelycontrolledwithprednisone.AbirateroneVialeBracci11,53100Siena,ItalyTel:+393494046532;fax:+390577586133;acetateseemstobeaneffectiveandwell-toleratede-mail:giandomenicoroviello@hotmail.
9、ittreatmentoptionforpatientswithmetastaticcastrate-resistantprostatecancerirrespectiveofReceived26September2013Revise
